Hematologic Oncology

FISH testing for genetic abnormalities is the key to appropriate treatment selection for patients with CLL.

Several molecular markers for AML are now used at top-tier cancer centers for prediction, treatment selection, and monitoring response.

Genetic markers are becoming a more integral part of diagnosing cancer and determining which patients will encounter more aggressive forms of their disease.

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses the Winter Hematology Meeting

Dr. Elena Lukina Discusses Timely Gaucher Disease Diagnosis

Dr. Laurie Sehn, from the British Columbia Cancer Agency, Discusses the GAUSS Obinutuzumab Trial

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses Brentuximab Vedotin

Dr. Daniel Couriel, from the Unversity of Michigan Comprehensive Cancer Center, Discusses Treating GVHD With Photopheresis

Bone disease occurs in about 84% of patients with multiple myeloma and is responsible for a great deal of morbidity, including pain, hypercalcemia, compromised quality of life, and pathological fracture.

Dr. Tatyana Feldman, from the John Theurer Cancer Center, Discusses Using Doxil for CTCL

Because of bendamustine's potential to cause pain and erythema to the extent that hospitalization has been required for some patients, it would be prudent to administer bendamustine using vesicant precautions.

Trainees have sat in this hot seat at the front of the room for decades. It's not really warm, of course. This is where the fellow sits who is asked to review the findings, come up with a differential diagnosis, and devise a plan for the case in question.

While debt from medical school loans is inevitable for most oncology and hematology fellows, there are strategies they can consider to lessen that burden.

Dr. Anthony Mato From the John Theurer Cancer Center Discusses the Benefits of the JTCC Retrospective Trial

The phase III VISTA trial upholds a persistent and statistically significant survival benefit for bortezomib in previously untreated multiple myeloma patients.

Treatment with GA101 (obinutuzumab) in patients with relapsed non-Hodgkin lymphoma (NHL) resulted in higher response rates compared with rituximab.

Dr. Claudio Anasetti from the H. Lee Moffitt Cancer Center Discusses the Trade-offs of BMT and PBSC

First drug targeting Bruton's tyrosine kinase (Btk) produced high rates of remission in patients with CLL.

Twelve-year results from a Canadian Cancer Society Research Institute study shows chemotherapy alone increases survival in patients with Hodgkin Lymphoma.

Dr. Laurie Sehn from the British Columbia Cancer Agency Discusses the Efficacy of the CD20 Agent GA101

Study finds that peripheral blood stem cell (PBSC) transplants increase the incidence of graft-versus-host disease (GVHD).

Dr. James Kochenderfer from the National Cancer Institute Discusses the B-cell Antigen CD19

Dr. Tatyana Feldman from John Theurer Cancer Center Discusses the Difficulties of Rare Lymphomas

Andre Goy, MD, MS, treats lymphoma patients at New Jersey's largest cancer center, Goy, 54, is also a translational researcher widely known for his work showing the first-ever evidence of activity of bortezomib.

This month's collection of trials in progress highlights trials presented at the 2011 American Society of Clinical Oncology Meeting.